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ABSTRACT  We carried out cytogenetic studies  of four Chinese hamster,  mouse,  and human 
cell  lines  selected  for high  levels  of resistance  (500- to 4,000-fold) to vincristine  (VCR) by a 
multistep  selection  procedure.  All  cells  examined  contained  gene  amplification-associated 
metaphase chromosome abnormalities, either homogeneously staining regions  (HSRs), abnor- 
mally  banding  regions  (ABRs), or double-minute  chromosomes  (DMs); control  actinomycin 
D- and daunorubicin-resistant  hamster lines did not exhibit this type of chromosomal abnor- 
mality.  VCR-resistant  Chinese  hamster  sublines  exhibited  both  increased  synthesis  of  the 
protein  V19  (Mr  19,000;  pl  =  5.7)  and  increased  concentrations  of V19  polysomal  mRNA. 
When VCR-resistant  cells  were grown in drug-free  medium,  level  of resistance,  synthesis  of 
V19, and amount of V19  mRNA declined  in  parallel  with  mean  length  of the  HSR or mean 
number  of  DMs  per  cell.  Cross-resistance  studies  indicate  that  VCR-resistant  cells  have 
increased  resistance  both to antimitotic  agents and to a wide variety of agents  unrelated  to 
VCR in chemical  structure and/or  mechanism  of action.  Our studies  of tubulin  synthesis  in 
Chinese hamster cells  indicate no overproduction  of tubulin or presence of a mutant tubulin 
species. Comparison with antifolate-resistant Chinese hamster cells known to contain amplified 
dihydrofolate  reductase  genes  localized  to  HSRs or ABRs strongly  suggests that  the  HSRs, 
ABRs, or DMs of the Vinca alkaloid-resistant  sublines  likewise represent cytological  manifes- 
tations  of specifically  amplified  genes,  possibly  encoding V19,  involved  in  development  of 
resistance  to VCR. 
Recognition of gene amplification as a mechanism whereby 
mammalian cells may develop resistance to cytotoxic agents 
began with the discovery of a novel chromosome abnormality, 
the homogeneously staining region (HSR) ~  (l). Appearing in 
trypsin-Giemsa banded cells as long chromosomal segments 
that stained with relative uniformity and intermediate inten- 
sity, HSRs were observed in Chinese hamster lung (CHL) cell 
lines with high levels of acquired resistance to antifolates and 
~  Abbreviations used in this paper  ABR,  abnormally banding region; 
CHL, Chinese hamster lung; DHFR, dihydrofolate reductase; DM, 
double-minute  chromosome;  EDso, half-maximal  effective dose; 
HSR, homogeneously staining region; 2D, two-dimensional; VCR, 
vincristine. 
high levels of target enzyme dihydrofolate reductase (DHFR) 
(1,  2).  It has been  demonstrated that  increased  activity of 
DHFR in resistant sublines derived in cell culture by progres- 
sive increases in  selective drug  concentration  is due  to  an 
increased rate of biosynthesis of the enzyme (3-5),  accom- 
panied by increase in cellular concentration of  DHFR-specific 
mRNA (6-8). The basis of these overproduction phenomena 
was found to be selective amplification of DHFR-encoding 
genes (9,  10). Moreover, in antifolate-resistant, HSR-contain- 
ing  hamster and  mouse cells,  HSRs are  sites  of amplified 
DHFR genes (1 l-14). 
Another distinctive  chromosomal abnormality indicative 
of DNA sequence amplification is the double-minute chro- 
mosome (DM) (15-17). DMs are small, paired extrachromo- 
THE JOURNAL OF  CELL BIOLOGY • VOLUME 100  FEBRUARY 1985 588-597 
588  © The Rockefeller University Press  . 0021-9525/85102]0588[I0  $1.00 somal chromatin bodies that appear to lack a  centromere. 
Variable in both number and size, DMs have been found in 
various methotrexate-resistant mouse ( 15,  18, 19) and human 
(20, 21) cell lines. Specific hybridization of cloned segments 
of the DHFR gene to DM-enriched DNA and quantitative 
correlations between DHFR level and number of DMs per 
cell (15,  16),  as well as hybridization in situ of Cot-purified 
amplified DNA to DMs of human neuroblastoma cells (17), 
have provided evidence that DMs carry amplified DNA se- 
quences. 
We  report  here  that  four Chinese  hamster,  mouse,  and 
human cell  lines with high  levels of acquired resistance to 
vincristine  (VCR)  contain  gene  amplification-associated 
chromosomal abnormalities and that these structures are lost 
in  revertants in  parallel  with  loss of resistance.  CHL  cells 
selected for resistance to actinomycin D  or daunorubicin do 
not contain  these  types of abnormalities.  Cells  of a  VCR- 
resistant CHL line, DC-3F/VCRd,  contain HSRs (22); cells 
of a second VCR-resistant CHL line described in this report, 
DC-3F/VCRm, contain abnormally banding regions (ABRs). 
ABRs have been shown to encompass low numbers of ampli- 
fied  genes  in  antifolate-resistant cells  derived  from  DC-3F 
(23). Mouse tumor and human cells selected with the  Finca 
alkaloid contain DMs (19, and this report). The presence of 
HSRs, ABRs, or DMs in the resistant cells is suggestive of the 
possibility that at least one mechanism of resistance to VCR 
involves gene amplification. 
A  possible  product  of amplified  genes  is  the  previously 
described  protein  Vl9  (Mr  19,000;  pI  =  5.7)  (24).  V19  is 
overproduced in VCR-resistant CHL and mouse tumor cells. 
Increased synthesis of V19-specific  mRNA  and  loss of the 
peptide  during  phenotypic  reversion,  as  described  in  this 
report, further associate V 19 and the drug-resistant phenotype 
in these cells.  In contrast, we have observed no relationship 
between resistance,  HSRs,  or DMs,  and  overproduction of 
tubulin, to which VCR binds (25,  26). Cabral et al. (27, 28) 
Connolly et al. (29), and Keates et al. (30) have found mutant 
tubulin  or altered  microtubules  in  cells  resistant  to  other 
antimitotics. VCR-resistant CHL cells, however, do not ap- 
pear to synthesize a mutant tubulin species. 
MATERIALS  AND  METHODS 
Derivation of Cell Lines and Clones:  Cell  lines  DC-3F/VCRd 
and DC-3F/VCRm are independently  derived  VCR-resistant  sublines of the 
CHL cell line, DC-3F (31). Both were selected by exposure to stepwise (2-2.5- 
fold) increases in VCR concentration  and are maintained  in  l0 ug/ml drug. 
Clonal sublines DC-3F/VCRd-I  and DC-3F/VCRd-5  were isolated from DC- 
3F/VCRd cells inoculated  into Falcon  Microtest  II plates in 5 ug/ml VCR. 
After initial  characterizations,  both clones were transferred  to drug-free me- 
dium, designated  DC-3F/VCRd-I-U and  DC-3F/VCRd-5-U,  and grown  in 
absence of  drug for 21/2 yr. Clone DC-3F/VCRd-5  was also further selected with 
higher concentrations  of VCR; the resulting, highly resistant subline designated 
DC-3F/VCRd-5L  grows in 50 #g/ml VCR. The actinomycin  D- and dauno- 
rubicin-resistant  CHL sublines  DC-3F/AD X (2,450-fold resistant) and DC- 
3F/DM XX (883-fold resistant) have been described (31, 32). DC-3F/AD XC 
(50.000-fold  resistant)  was  selected  from  DC-3F/ADX  cells by  multistep 
increases in concentration  of actinomycin  D from 10 to 100 ug/ml. The drug- 
sensitive mouse tumor line, MAZ, was clonally isolated from cells established 
in vitro from a hydrocarbon-induced tumor  ofa C57BL/6 mouse (22). Selection 
with VCR yielded the resistant cell line, MAZ/VCR,  now maintained  at 20 
~g/ml drug.  The VCR-resistant  human neuroblastoma  cell line  SH-SY5Y/ 
VCR was selected from SH-SY5Y, a clonal subline of the neuroblastoma  line 
SK-N-SH (33, 34). Revertant  sublines MAZ/VCR-U and SH-SY5Y/VCR-U 
were initiated from drug-treated sublines without  prior cloning and grown in 
drug-free medium for  14 and 8 mo, respectively. VCR-resistant cell lines are 
listed in Table I. 
Cell  Culture  Techniques:  Chinese  hamster and  mouse cells are 
cultured  either in Eagle's minimum essential medium or in a  1:1  mixture  of 
that  medium and  Ham's FI2  medium,  supplemented  with  5 or  10%  fetal 
bovine  serum,  100  IU/ml penicillin,  and  100  #g/ml  streptomycin.  Drug- 
resistant sublines are routinely maintained  in presence of drug but are grown 
in drug-free medium for 10-15  d (CHL  cells) or 2-4 d  (MAZ cells) before 
experimentation.  Procedures for determination  of drug sensitivity have been 
described (31). To obtain EDs0 (half-maximal effective dose) values, we carried 
out two or three independent  dose-response assays for each cell line. Modifi- 
cations of experimental  conditions  for the more slowly growing human neu- 
roblastoma cells include increase in serum concentration  to 15% and a longer 
period of growth (6 d) in dose-response assays. VCR was generously provided 
by Eli Lilly and Co. 
Chromosomal Analyses:  Cells  for karyotype studies were prepared 
and stained by standard procedures (35) modified from the method of  Seabright 
(36), with or without pretreatment  with 0.001-5  t~g/ml Colcemid. Preparations 
were stained both by trypsin-Giemsa techniques for chromosome identification 
and  by  conventional  methods  to better  assess DM  size and  number. HSR 
length was determined from photographs of 15-20 metaphase plates per sample, 
as described earlier (35). Chinese hamster chromosome nomenclature  has been 
modified from earlier, published analyses (22) as suggested by Ray and Mohan- 
das (37). Human chromosome nomenclature  follows the conventions of ISCN 
(1978): An International  System for Human Cytogenetic Nomenclature (1978) 
(38). 
Chromosomal DNA  replication  patterns  were  determined  as previously 
described ( 1, 2). 
Protein Analyses:  Cells  were grown in methionine-deficient  growth 
medium containing  10/~Ci/ml [35S]methionine  (New England Nuclear, Boston, 
MA) for 4 h, except where noted, then harvested and lysed by sonication  as 
previously described (24) unles  s otherwise stated. Two-dimensional  (2D) gel 
electrophoresis was carried out according to the  methods  of O'Farrell  et al. 
(39). The completed 5-13% acrylamide gradient slab gels (0.75 x 14 x 35 cm) 
were treated  with sodium  salicylate (Aldrich Chemical Co., Inc., Milwaukee, 
WI) (40), dried,  and  exposed at  -70"C  with  X-OMAT  AR  film  (Eastman 
Kodak Co., Rochester, NY). The 2D gels are oriented  with basic proteins at 
left and acidic proteins at right, in each panel. The acid side of the 2D gels in 
this report is on the right. 
Microtubules  from  radiolabeled  DC-3F  and  DC-3F/VCRd-5  cells were 
assembled through one cycle of polymerization as described by Shelanski et al. 
(41). The microtubule  pellets were solubilized in O'Farrell  buffer (39) before 
2D gel analysis. In some experiments, cells were treated with 5 ~g/ml colchicine 
to stop de novo synthesis of tubulin, then lysed with detergent (42). Absence of 
TABLE  I 
Drug Resistance Levels and Presence of Resistance-related Cy- 
togenetic  Abnormalities  in Vincristine-resistant and Control Cell 
Lines 
Selective  Chromo- 
concen-  Increase in  somal ab- 
Cell line  tration  resistance*  normality 
#glml 
Chinese hamster 
DC-3F  0  1  -- 
DC-3F/VCRd  10  650*  HSR 
DC-3F/VCRd-1  5  650  HSR 
DC-3F/VCRd-5  5  500*  HSR 
DC-3F/VCRd-5L  50  2,750*  HSR 
DC-3F/VCRd-1 -U  0  1  -- 
DC-3F/VCRd-5-U  0  33  -- 
DC-3F/VCRm  10  550  ABR 
Mouse 
MAZ  0  1  m 
MAZ/VCR  20  3,939  DMs 
MAZ/VCR-U  0  4  -- 
Human 
SH-SY5Y  0  1  -- 
SH-SY5Y/VCR  10  1,333  DMs 
SH-SY5Y/VCR-U  0  8  -- 
* Degree of resistance was determined in dose-response assays as described 
previously (31 ). 
* Previously published values (19, 47, 48). 
Control  MAZ  cells  contain  a  low  number  of  DMs;  however,  both  the 
number  of  DMs  and  the  frequency of  DM-containing  cells  are  greatly 
increased in the resistant subline. See text. 
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in identification of those peptides. Identity of a- and/3-tubulin spots on the 2D 
gels was confirmed by co-electrophoresis of pig brain tubulin, prepared accord- 
ing to Shelanski et al. (41), with labeled  CHL cell protein. 
In  Vitro  Translation:  Procedures for  polysome isolation,  mRNA 
purification, and cell-free  protein synthesis were carried  out as described by 
Melera et al. (8). 
RESULTS 
Resistance and Cross-resistance of Cell Lines 
Selected with VCR 
As  part  of an  ongoing  investigation  to  uncover genetic 
mechanisms of resistance to a variety of cancer chemothera- 
peutic agents, we independently selected two VCR-resistant 
sublines,  DC-3F/VCRd  and  DC-3F/VCRm,  from  DC-3F, 
one VCR-resistant line from the mouse tumor line,  MAZ, 
and a fourth subline from the cloned human neuroblastoma 
line, SH-SY5Y. Levels of resistance of drug-treated cells range 
from 500- to 4,000-fold (Table I). 
To assess the presence and extent of the multidrug-resistant 
phenotype in cell  lines selected with the  Vinca alkaloid, we 
carried  out  cross-resistance  assays  on  the  650-fold  VCR- 
resistant  DC-3F/VCRd  CHL cells and,  to  a  more limited 
extent, on VCR-resistant mouse and human cells. In general, 
degree of cross-resistance of DC-3F/VCRd cells is greatest for 
drugs known to affect microtubule polymerization; indeed, 
the VCR-resistant cells show reduced sensitivity to all antimi- 
totic drugs and experimental analogs tested (Table II). DC- 
3F/VCRd  cells  are  cross-resistant,  to  a  lesser extent,  to  a 
variety of other agents. The low levels of cross-resistance to 
6-thioguanine,  arabinosylcytosine,  methotrexate,  and  1,3- 
bis(2-chloroethyl)-l-nitrosourea are probably not significant 
(31).  The  mouse and  human  VCR-resistant cell lines,  like 
CHL cell sublines, are cross-resistant to actinomycin D, ex- 
hibiting increases of 571- and 200-fold, respectively, as com- 
pared with controls. 
Chromosomal Abnormalities  Characterizing VCR- 
resistant Cell Lines 
CHINESE  HAMSTER  SUBLINES:  Routine  karyotypic 
analysis of the 650-fold resistant subline, DC-3F/VCRd, re- 
vealed the presence of an HSR (Fig.  1).  HSRs were subse- 
quently observed in cells of all DC-3F/VCRd sublines (DC- 
3F/VCRd-1, DC-3F/VCRd-5, DC-3F/VCRd-5L). The HSR 
is located interstitially on a  marker chromosome and com- 
prises, on average, 2.7% of the total chromosome length in a 
cell.  It stains uniformly although somewhat more intensely 
than a typical HSR in antifolate-resistant CHL cells ( 1, 2, 35). 
The HSR of DC-3F/VCRd cells commences and completes 
DNA replication early in S-phase as shown by [3H]thymidine- 
labeling studies (Fig. 2, a-c). 
The labeling studies also demonstrated that the segment of 
the  marker  chromosome  arm  distal  to  and  including  an 
apparent secondary constriction region (Fig.  1) is clearly late- 
replicating (Fig. 2c). This segment thus most probably com- 
prises the distal half of the long arm of an X  chromosome 
(bands Xq21-Xqter) that, in normal cells, stains similarly to 
an HSR. The origins of the grey band proximal to Xq21 (the 
secondary constriction region) and of a wide, palely staining 
band between the HSR and a seemingly normal entire chro- 
mosome 8  are  ambiguous.  The  marker chromosome thus 
comprises  a  t(X;8;HSR;?)(8qter---,8pI9::?::HSR::?::Xq21---~ 
Xqter). 
Chromosomal analysis of the  second,  independently-de- 
rived VCR-resistant CHL cell line, DC-3F/VCRm, revealed 
the  presence of an  ABR,  a  long,  obscurely banded  region 
comprising 3.8%  of the total chromosome length, on a pre- 
TABLE  II 
Resistance of DC-3F/VCRd Cells to Chemotherapeutic and Cytotoxic Agents 
Molecular  Increase in 
Agent  weight  EDs0* for DC-3F/VCRd  EDso for DC-3F  resistance* 
#g/ml  10  -6 M  ~g/ml  10  -6 M 
Antimitotic agents 
Vincristine sulfate  922  13  14  0.020  0.022  650 
Vindesine sulfate  851  7.8  9.2  0.014  0.017  557 
Vinblastine sulfate  980  2.2  2.4  0.0043  0.0047  512 
Colchicine  399  7.0  18  0.020  0.050  350 
LY 108555 s  1,820  19  10  0.065  0.036  292 
VP-16-213  588  7.9  13  0.057  0.097  139 
LY 119863 ~  906  11  12  0.15  0.17  73 
Demecolcine  371  0.36  0.97  0.013  0.034  28 
Other agents 
Mithramycin  1,089 m  30  28  0.068  0.062  441 
Actinomycin D  1,256  0.30  0.24  0.0024  0.0019  125 
Puromycin  471  160  330  1.5  3.1  107 
Daunorubicin  528  2.1  4.0  0.023 ~  0.044  91 ~ 
Ethidium bromide  394  20  51  0.30  0.76  67 
Hydroxyurea  76  12  160  2.0  26  5.9 
6-Thioguanine  167  0.091  0.54  0.044  0.26  2.1 
Arabinosylcytosine  243  0.076  0.31  0.040  0.16  1.9 
Met hot  rexate  454  0.012  0.026  0.0067  0.015  1.8 
1,3-Bis(2-chloroet hyl)- 1  -nitrosou rea  214  2.4  11  1.9  8.9  1.3 
* ED5o: concentration effective in reducing cell growth to S0% of that of drug-free controls, as measured  in a 3-day assay. 
* EDso of DC-3F/VCRd::EDso  of DC-3F. 
!  Experimental Vinca alkaloid derivatives provided by Dr. George goder of Eli Lilly and Co. 
a Tentative molecular weight. 
• Revised from earlier publication (31). 
590  THE JOURNAL OF  CELL BIOLOGY • VOLUME 100, 1985 FIGURE  1  Trypsin-Giemsa banded  karyotypes of the  drug-sensitive CHL  cell  line  DC-3F  and  vincristine-resistant sublines. 
Asterisks indicate consistent, structurally altered chromosomes; brackets delineate the HSR (DC-3F/VCRd  and DC-3F/VCRd-5L) 
or ABR (DC-3F/VCRm).  The number in  parentheses  denotes degree of resistance to vincristine. The translocation involving the 
first chromosome 6 in the DC-3F/VCRm  cell shown is unique to this cell. ×  1,500. 
sumptive chromosome  10p21  (Fig.  1).  In these  cells,  both 
chromosome 8 homologues are normal. Moreover, although 
the single X  chromosome has been rearranged distal to the 
secondary  constriction  region  of the  long  arm,  the  region 
between  the  centromere and  band  Xq22  is  normal.  Thus, 
there appears to be no correspondence between the locations 
of the HSR in DC-3F/VCRd cells and the ABR in DC-3F/ 
VCRm cells.  Control  DC-3F cells and the  actinomycin D- 
and daunorubicin-resistant lines DC-3F/AD X  and DC-3F/ 
DM XX, also used as controls in  these studies, contain  no 
anomalous regions (nor DMs). Even the 50,000-fold resistant 
DC-3F/AD  XC  cells  have  no  chromosomal  regions  with 
abnormal band patterns corresponding to the ABR of DC- 
3F/VCRm. 
Both of the VCR-resistant CHL sublines contain numerous 
structurally altered chromosomes, including two that are com- 
mon to all  DC-3F sublines (Fig.  1).  DC-3F/VCRd sublines 
also  contain  2-3  small  supernumerary  chromosomes. 
Whether these small, abnormal chromosomes or unidentifi- 
able segments present on rearranged chromosomes represent 
ABRs is an open question. 
MOUSE TUMOR LINES:  Drug-sensitive MAZ cells have 
a  modal  chromosome  number  of 67-70  and  contain  an 
average of 24 DMs per cell in 65% of cells. DM number and 
frequency increased markedly after exposure to VCR;  100% 
of MAZ/VCR cells,  selected at 20 •g/ml  VCR and ~4,000- 
fold resistant to drug (Table I), are characterized by an average 
of 183  very small DMs near the resolving limit of the light 
microscope (Fig.  2d).  Of 100  cells  examined,  no cell con- 
tained <50 DMs, and two-thirds of the cells had >100 DMs 
MEYERS ET AL.  Gene Amplification  in Vincristine-resistant Cells  591 FIGURE  2  Tritiated thymidine labeling of DC-3F/VCRd chromosomes (a-c) and DMs in VCR-resistant mouse (d) and human (e) 
tumor cells. Cells in a, b, and c were labeled for 10 rain with 1 #Ci/ml [3H]thymidine, swelled and fixed after 3-15 h as described 
previously (1, 2). Chromosome regions replicating (a) early, (b) midway, and (c) late in S-phase. The HSR is indicated by a large 
arrow; the late replicating Xq chromosome segment in c is indicated by a small arrow. (d) A conventionally stained cell of the 
mouse MAZ/VCR cell line with more than 250 barely visible DMs. (e) A conventionally stained cell of the DM-containing human 
SH-SY5Y/VCR subline. Bar, 10 ~m. 
per cell.  Resistant cells do not exhibit long HSRs or obvious 
ABRs; short HSRs or ABRs, however, could be present but 
not as yet identified owing to the type and extent of rearrange- 
ment characteristic of MAZ cells. 
HUMAN  NEUROBLASTOMA  CELL  LINES:  A  VCR-resistant 
subline was also selected over a 7-yr period from the human 
neuroblastoma line, SH-SY5Y. Unlike most human neuro- 
blastoma cell lines described  so far (43),  hyperdiploid  SH- 
SY5Y  cells  and  the  SK-N-SH line  from which  the  thrice- 
cloned  subline  was  isolated  have  never  been  observed  to 
contain  HSRs or DMs (34).  The  1,300-fold  resistant  cells, 
however, are characterized by an average of 40 DMs per cell 
in 100% of cells (Fig. 2e); no cell contains <10 DMs, 30% of 
cells have >50, and 6% have >100 DMs. 
Protein Changes in VCR-resistant CHL Cells 
A  possible  protein  product  of amplified genes  in  VCR- 
resistant cells is a protein we have designated V19 (24).  Vl9 
is seen on 2D gels of cytosol proteins of DC-3F/VCRd-5 cells 
(Fig.  3)  and of the  more highly resistant  DC-3F/VCRd-5L 
cells.  Further,  DC-3F/VCRm  cells  also synthesize  V19,  al- 
though  in  lesser  amounts  (data  not  shown).  The  relative 
abundance of V19  seen on  these gels  reflects an  increased 
abundance of V 19 mRNA in the VCR-resistant cells. 2D gels 
of translation products of polysomal mRNA from DC-3F/ 
VCRd-5L cells  show a  prominent V19 spot (Fig.  4b) com- 
pared  with  control  (Fig.  4a),  whereas  DC-3F/VCRm  cell 
material had lower levels of V19-specific mRNA (data not 
shown). Two other proteins are also overproduced in DC-3F/ 
VCRd-5 cells:  V61  (Mr 61,000;  pI =  7.2)  (Fig.  3) and V92 
(Mr 92,000; pI =  7.1) (not shown). V61, however, is not seen 
on gels  from DC-3F/VCRm,  and  neither  V61  nor  V92  is 
identifiable on gels of translation products of DC-3F/VCRd- 
5L polysomal mRNA (Fig.  4).  V19 is also readily identified 
on 2D gels of MAZ/VCR cell proteins (Fig. 5); V61 and V92 
are not  seen on MAZ/VCR gels.  In earlier studies,  cytosol 
592  THE  JOURNAL OF  CELL BIOLOGY . VOLUME 100, 1985 FIGURE 3  Two-dimensional  gel electrophoretic separation of [3sS]- 
methionine-labeled soluble proteins from  (a)  DC-3F,  (b)  DC-3F/ 
VCRd-5,  and  (c)  DC-3F/VCRd-5-U  cells  lysed  by sonication.  Ali- 
quots of supernatant  material obtained after centrifugation of cell 
homogenates, containing  -5 x  I0  s cpm (30-50/zg of protein), were 
applied to the first dimension gels. Completed gels were exposed 
to  x-ray  film  for  four d.  Complete procedures  are described  in 
Materials and Methods. The numbers  on the photographs are for 
orientation purposes only. Spot 11, designated A, is known to be 
actin.  V61  and  V19 positions  are enclosed.  Dotted lines enclose 
areas of gel depicted in Fig. 5 (Vl 9 area) and dashed lines delineate 
areas shown in Figs. 6 and 7 (tubulin area). Acid side of the 2D gels 
is on the right. 
polymerized  microtubule  pellet,  and  V19  synthesis  is  not 
altered by colchicine treatment (data not shown). 
Reversion of Resistance and Loss of HSR, DMs, 
and V19 Expression 
To assess  the stability of the  VCR-resistant phenotype in 
absence of drug  selection  pressure,  we  cloned  the  DC-3F/ 
VCRd  subline  in  the  presence of 5  #g/ml VCR.  We then 
transferred  two  clonally  derived  sublines,  DC-3F/VCRd-1 
and DC-3F/VCRd-5, to drug-free medium and redesignated 
them  DC-3F/VCRd-l-U  and  DC-3F/VCRd-5-U  (Table  I). 
Levels of resistance declined between the first two assays done 
after 3 and 9 wk in the absence of VCR (Table III). During 
the first 4  mo of the 2t/2-yr experimental period, the rate of 
decrease was more rapid for DC-3F/VCRd-l-U than for DC- 
3F/VCRd-5-U cells (t~/2  =  60 and  120 d, respectively). After 
an initial decline, resistance of DC-3F/VCRd-1-U cells stabi- 
lized for 8  mo at an intermediate level, and again declined 
rapidly until  reaching control level (Table III). In contrast, 
the resistance level of DC-3F/VCRd-5-U cells decreased pro- 
FIGURE 4  Fluorograms of 2D gels of protein products  of in vitro 
translations directed by poly(A  +) RNA from (a) DC-3F, (b) DC-3F/ 
VCRd-5L, and (c)  DC-3F/VCRd-5-U  cells.  Equal amounts of RNA 
were used for each reaction (~2/.tg) and equal amounts of trichlo- 
roacetic acid-precipitable radioactivity in translated  products  (2-3 
x  I0  s cpm) were subjected to electrophoresis. Arrows point to V19. 
Additional procedural information is in Materials and Methods. 
FIGURE 5  Details of fluorograms  of [3SS]methionine-labeled solu- 
ble proteins  from (a) MAZ and (b) MAZ/VCR separated by 2D gel 
electrophoresis.  Experimental details are as described  in Fig. 3. The 
numbers on the photographs are for orientation purposes. V19 and 
its  expected location in  MAZ  are  circled.  Area  of this  detail  is 
enclosed by dotted lines in Fig. 3. 
proteins  of the  VCR-sensitive  and  -resistant  hamster  and 
mouse cell lines were examined by sodium dodecyl PAGE. 
In addition to Vl9, two other protein species (Mr 43,000 and 
32,000-35,000) were present in increased amounts in resistant 
cells (data not shown). These two proteins are not consistently 
identifiable on 2D gels but are of potential future interest. 
The high degree of cross-resistance of DC-3F/VCRd cells 
to various antimitotic agents (Table II) and studies in other 
laboratories  (27-30)  suggested  the  possibility  that  tubulin 
protein  was  overproduced  or altered  in  the  resistant  cells. 
Analysis by 2D gel electrophoresis of polymerization-compe- 
tent tubulin (Fig.  6) or of unpolymerized tubulin in absence 
and presence of colchicine (Fig.  7)  showed no evidence for 
either overproduction or mutation of a- or/~-tubulin in VCR- 
resistant CHL cells. V 19 does not copolymerize with tubulin; 
it  remains  in  the  supernatant  material  above the  in  vitro 
FIGURE 6  Details of fluorograms  of [3SS]methionine-labeled pro- 
teins  in  microtubule  pellets  obtained  by  one  cycle  of  in  vitro 
assembly and separated by 2D gel electrophoresis.  Equal  amounts 
of trichloroacetic acid-precipitable radioactive proteins (about I  x 
I0  s  cpm/sample)  from (a) DC-3F and (b) DC-3F/VCRd-5L cells were 
analyzed.  Complete procedures  are given in Materials and Meth- 
ods. 
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ble  proteins  separated  by  2D  gel  electrophoresis from  (a  and  b) 
DC-3F and (c and d)  DC-3F/VCRd-5  cells either treated (b and d) 
or untreated (a and c) with 5 ~g/ml of colchicine for 5.5 h before a 
30-min  exposure to radioactive methionine. The cells  were lysed 
by treatment with Nonidet P-40 (30) and soluble material containing 
5-6  x  10  s cpm  per  aliquot  was  applied  to  first  dimension  gels. 
Procedures for these experiments were described by Ben-Ze'ev et 
al. (42) as stated in Materials and Methods. Numbers are used for 
orientation  purposes.  Spot g  is  actin,  a  is  ~x-tubulin and  /3  is  /3- 
tubulin.  Two forms  of c~-tubulin  (c~1 and  ~2) are evident in  DC-3F 
untreated  gels  and  are  not  observed  on  the  gels  of  colchicine- 
treated cell samples, a-Tubulin was frequently not observed or was 
seen as an indistinct spot on DC-3F/VCRd-5L gels. 
TABLE III 
Concomitant Decrease  in Resistance to Vincristine and in HSR 
Length in Two Clones Isolated from the DC-3F/VCRd  Cell Line 
DC-3F/VCRd-1 -U  DC-3F]VCRd-5-U 
Degree  Degree 
of  of re- 
Time off  resist-  HSR length*  sist-  HSR length* 
drug  ance*  +  SD  ance*  +  SD 
weeks 
0-3  650  0.52 --- 0.057  500  0.68 +  0.11 
9  345  425 
12-13  290  0.45 +  0.12  385  0.62 +  0.20 
18-24  175  325 
28-3O  150  O.33 +  0.099  150  0.37 +  0.13 
35-39  150  100 
49-55  180  55  0.043 --- 0.064  s 
67-78  110  32 
119  1.2  0.073 +  0.0032  33 
* EDso of resistant  cells::EDso of parental DC-3F cells. 
* Length of the HSR::average  length of chromosome 2p. 
! At this time point, only 40% of cells contained HSRs. 
mosome band cannot be determined at this time. The revert- 
ant cells,  however, retained the structurally rearranged chro- 
mosomes  1,  6,  and  7  that  are  characteristic  of the  drug- 
resistant progenitors but not seen in drug-sensitive cells. The 
presence  of these  marker  chromosomes  and  of the  8-Xq 
chromosome indicated unequivocally that the revertant cells, 
even those that had completely lost resistance, were derived 
from the resistant cells and were not cell contaminants. 
Decrease in resistance and in HSR length in DC-3F/VCRd- 
5-U cells was also accompanied by a decrease in V 19 synthesis 
(Fig.  3 c) and a decreased concentration of V I9 mRNA (Fig. 
4 c). The amount of the other two proteins, V61 (Fig. 3 c) and 
V92,  remained  elevated,  even in  cells with  only a  33-fold 
residual resistance level. 
Both DM-containing VCR-resistant sublines, mouse MAZ/ 
VCR  and  human  SH-SY5Y/VCR,  also  underwent  pheno- 
typic reversion when grown in drug-free medium. Decline in 
resistance was rapid for both lines, with tl/2 =  10 d for MAZ/ 
VCR-U and  30 d  for the  more slowly growing human SH- 
SY5Y/VCR-U cells. Resistance of the MAZ/VCR-U subline 
stabilized at a level fourfold higher than that of control MAZ 
cells (Table IV) after -5  mo and remained at that level for 
another 9 mo, at which time the experiment was terminated. 
Decrease in  resistance was paralleled by a  decrease  in  DM 
number and frequency (Table IV; Fig.  9) and by a decrease 
in synthesis of V19 (Fig. 9). The VI9 spot, as seen in Fig. 5 b, 
is absent in MAZ/VCR-U protein gels (not shown). 
DISCUSSION 
Resistance and cross-resistance patterns observed for DC-3F/ 
VCRd cells, in the present study, differ from those previously 
reported for actinomycin D- and daunorubicin-resistant CHL 
cells  (22,  44).  The levels of resistance or cross-resistance of 
DC-3F/VCRd cells to actinomycin D  and daunorubicin are 
low compared with VCR itself and other antimitotics such as 
vindesine and colchicine, suggesting that there is a resistance 
mechanism  in  these  cells  involving  microtubule  function 
alteration. Actinomycin D-resistant (DC-3F/AD X) and dau- 
norubicin-resistant (DC-3F/DM XX) cells, on the other hand, 
show relatively high  levels of cross-resistance to  vincristine 
and other alkaloids. This suggests that drug exclusion plays a 
more important role in expression of resistance in the anti- 
biotic-resistant  cells.  In  general,  all  of the  cross-resistance 
gressively for ~ 11/2 yr, ultimately stabilizing at a level 33-fold 
higher than that of control DC-3F cells (Table III). 
Decrease in resistance was paralleled by a decrease in the 
mean length of the HSR (Table III). At any one time point 
during the reversion process, there was considerable hetero- 
geneity  among  cells  with  respect  to  HSR  length  (Fig.  8). 
However, diminution in length of the HSR was not associated 
with  obvious chromosomal breakage  or  rearrangement.  In 
nearly  all  cells  examined,  the  composition  of the  marker 
chromosome, i.e.,  8-HSR-Xq,  remained constant;  only the 
length of the interstitial HSR was altered. After 28 mo, HSRs 
had diminished in size to the approximate width of a normal 
chromosome band, situated between the secondary constric- 
tion (band Xq21) of the X  chromosome and the elongated, 
palely  staining  8p+  region.  Whether  the  remaining  band 
represents residual  HSR  material or a  normal  Xql 8  chro- 
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FIGURE  8  Decrease in HSR length in revertant (a) DC-3F/VCRd-1- 
U  and (b) DC-3F]VCRd-5-U  cell lines during growth in vincristine- 
free medium.  Brackets denote HSRs. TABLE IV 
Decrease in Resistance and DM Number in Murine MAZIVCR Cells in Absence of Drug 
Time off drug 
Degree of  Frequency (%) of cells with: 
resistance*  0 DMs  1-10 DMs  11-50 DMs  51-100 DMs  101-200 DMs 
Mean number 
>200 DMs  of DMs 
weeks 
0  4,545  0  0  0  34  42  24  183 
0.5  3,333  0  6  20  30  26  18  139 
1.5  2,515  0  0  17  33  23  27  171 
2.0  1,576 
3.0-3.5  1,242  0  4  44  34  16  2  59 
4.0  939  2  20  58  16  4  0  34 
7.5-8.0  333  4  18  44  26  8  0  43 
12.0  76 
19.0-57.0  4 
Control*  1  35  24  30  5  5  1  24 
* EDso of resistant cells::EDso  of drug-sensitive parent cells. 
* Drug-sensitive MAZ cells. 
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FIGURE  9  Decrease in level of resistance (0), in numbers of DMs 
(r-I), and  in  synthesis of V19  ((D) in  MAZ/VCR  cells  grown  in  the 
absence of drug.  For determination of amounts of V19, cells were 
metabolically labeled with  [3SS]methionine; aliquots of soluble ra- 
diolabeled  proteins,  containing 5  x  10  s cpm,  were  subjected  to 
two-dimensional or one-dimensional gel electrophoresis. Two-di- 
mensional gel spots corresponding to V19 were cut out and counted 
(values plotted here), or bands from single dimension gels were first 
visualized by Coomassie Blue stain and then cut out and counted. 
The intensity of stain in the V19 band decreased with time as did 
the amount of radioactivity (data not shown). Data are reported as 
a percent of values obtained for MAZ/VCR cells grown continuously 
in the presence of drug. 
results are  consistent with  the  idea that there  are  multiple 
pathways  for  the  development  of resistance  in  multidrug 
resistant cells. 
The  cytogenetic and  reversion data  strongly implicate a 
gene amplification mechanism in development of resistance 
to VCR. Four independently derived, VCR-resistant cell lines 
selected from CHL, mouse tumor, or human neuroblastoma 
parental populations are characterized by gene amplification- 
associated chromosomal abnormalities that disappear in ab- 
sence of selection pressure. Preliminary evidence from in situ 
hybridization experiments with the use of Cot-purified ampli- 
fled DNA from DC-3F/VCRd-5L cells as probe confirms the 
presence of amplified DNA sequences in the HSRs of VCR- 
resistant CHL cells (Scotto, K. W., and P. W. Melera, unpub- 
lished observations). 
VCR-resistant CHL cells share many of the characteristics 
of  HSR- and ABR-containing antifolate-resistant sublines also 
derived from control DC-3F cells:  (a) as in highly resistant 
methotrexate- and methasquin-resistant DC-3F cells  (1,  35) 
and in numerous other cell lines selected with methotrexate 
(11-13, 45, 46) and known to contain amplified genes coding 
for DHFR,  DC-3F/VCRd  and DC-3F/VCRd-5L cells with 
the  highest level of VCR  resistance contain  an  HSR on  a 
single chromosome; (b) the HSRs of the VCR-resistant cells 
stain homogeneously but somewhat more darkly than those 
typifying antifolate-resistant cells; they comprise ~3% of the 
total chromosome length (22) compared with 4-5% for the 
antifolate-resistant cells (35); (c) DNA of the HSR character- 
izing both methotrexate- and VCR-resistant cells is replicated 
synchronously and starts replication early during the S-period 
(1) (Fig. 2), consistent with the possibility that it is a transcrip- 
tionally active region; (d) like antifolate-resistant CHL sub- 
lines with low levels of resistance (23,  25),  a  second, inde- 
pendently  derived  VCR-resistant  subline,  DC-3F/VCRm, 
with a slightly lower level of resistance, has an ABR; (e) when 
clonally derived  sublines  of DC-3F/VCRd  were  grown  in 
drug-free medium, there was a decline in resistance and mean 
length of the HSR (Table III), as previously demonstrated for 
antifolate-resistant DC-3F sublines (35). 
The VCR-resistant CHL cell system differs from the anti- 
folate-resistant system in  the  chromosomal location of the 
HSR or ABR. In the latter, the regions are preferentially (but 
not always) located on a particular arm of chromosome 2 (1, 
11,  35).  In  the  VCR-resistant  cells,  chromosome 2  is  not 
involved.  However,  we  have  only  two  independent  VCR- 
resistant sublines and thus cannot infer the permanent loca- 
tion of a putatively amplified gene. 
There are also clear similarities between the VCR-resistant 
mouse MAZ/VCR subline and the previously described an- 
tifolate-resistant subline MAZ/A/MQ (19), both derived from 
the  same  control  cell  line  MAZ.  The  4,000-fold  resistant 
MAZ/VCR cells contain high and variable numbers of DMs 
(an average of 183 per cell). The 50,000-fold resistant MAZ/ 
A/MQ cells average >300 DMs per cell (19); the association 
between the presence of DMs and amplification of  the DHFR- 
encoding gene is well-established ( 15,  18, 20, 21). When each 
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there was a  rapidly initiated and rapidly progressive loss of 
resistance and mean number of DMs per cell (Table IV) (l 9). 
One important attribute that may distinguish gene ampli- 
fication-associated drug resistance from resistance developing 
as a  consequence of other genotypic  alterations,  e.g.,  base 
substitution or deletion, is instability of the resistant pheno- 
type in the absence of drug selection pressure (19). In all four 
cell  lines  tested  for stability  of resistance,  two  of the lines 
derived from mass cell populations and two isolated as clonal 
subpopulations, resistance decreased markedly during growth 
in drug-free medium. For two cell lines, sensitivity to VCR 
returned to near-control levels, suggesting that in these lines, 
DC-3F/VCRd-I-U  and SH-SY5Y/VCR-U,  amplification of 
one or several genes may be the major mechanism of resist- 
ance. In DC-3F/VCRd-5-U  cells,  however, resistance stabi- 
lized  at  a  level  30-fold  higher  than  that  of the  controls. 
Whether this residual resistance indicates the operation of a 
second resistance mechanism not associated with gene ampli- 
fication or presence of a  small number of amplified  genes 
integrated  into  one  or  more  chromosomally  undetectable 
sites, an apparently stable arrangement in antifolate resistant 
cells (19), is unknown. 
One candidate protein product of the amplified genes is 
V19. This previously reported (24) cytosolic protein is over- 
produced in VCR-resistant CHL and mouse tumor cells. Its 
synthesis reflects increased abundance of V 19 mRNA in those 
cells. Although levels of V19 synthesis are closely associated 
with levels of resistance to VCR and with number of DMs in 
the mouse tumor cell system, as indicated by the reversion 
study, the role this peptide plays in expression of resistance, 
if any, is not yet known. However, the consistent finding of 
increased  synthesis of V19  in  VCR-resistant  cells  warrants 
continued investigation of this protein species. 
In contrast to studies in other laboratories of cells resistant 
to other antimitotics (27-30),  our studies have not demon- 
strated  any  apparent  mutant tubulin  species  in  the  VCR- 
resistant CHL cells,  nor do they indicate overproduction of 
tubulin.  Thus a  major mechanism conferring resistance on 
DC-3F/VCRd-5  cells may be associated with microtubules, 
but is probably not directly involved with tubulin proteins. 
A second protein, somewhat less compelling as a candidate 
product  of amplified  genes,  is  the  high  molecular weight 
glycoprotein  species,  gpl50,  characterizing  drug-resistant 
CHL cells selected with actinomycin D  or daunorubicin as 
well as with VCR (22, 47). Chromosomal structures indicative 
of gene amplification have not been  seen in the CHL cells 
resistant to either daunorubicin or actinomycin D,  even in 
cells  raised  to  an  extraordinarily  high  level  of  resistance 
(50,000-fold) to the latter drug.  Nevertheless, the phenotypic 
similarities between resistant CHL cells selected with each of 
the  three  drugs  (19,  22,  44,  48),  the  instability  of gpl50 
expression in  revertant CHL cells grown in the absence of 
either actinomycin D or VCR (19, 22, 44, 47), and the finding 
of an HSR in drug-resistant Djungarian hamster cells selected 
with actinomycin D  (49) all raise the possibility that gpl50 
could be the product of amplified genes that are not detected 
by current cytogenetic procedures in the actinomycin D- or 
daunorubicin-resistant CHL cells. 
Taking into account all the above considerations, our over- 
all results strongly support the view that the VCR-resistant 
cells have undergone more than one genetic alteration (49). 
One alteration is related to drug uptake differences and cross- 
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resistance  phenomena  and  affects  most  or  all  multidrug- 
resistant cells. A  second one involves gene amplification as- 
sociated with overproduction of V l9  or some other as yet 
unidentified protein. This second change contributes to the 
phenotype  of the  VCR-resistant  cells  under  study  in  our 
laboratory and  of certain  other multidrug-resistant cells as 
well (44, 50, 51). 
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